Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 39, Issue 36, Pages 4061-4068
Publisher
American Society of Clinical Oncology (ASCO)
Online
2021-10-02
DOI
10.1200/jco.21.00468
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of Salivary Gland Malignancy: ASCO Guideline
- (2021) Jessica L. Geiger et al. JOURNAL OF CLINICAL ONCOLOGY
- Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment
- (2020) Masato Nakaguro et al. CANCER CYTOPATHOLOGY
- Androgen Receptor in Breast Cancer: From Bench to Bedside
- (2020) Mengyao Chen et al. Frontiers in Endocrinology
- Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
- (2019) Alan Loh Ho et al. JOURNAL OF CLINICAL ONCOLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomarker Immunoprofile and molecular characteristics in salivary duct carcinoma: Clinicopathologic and prognostic implications
- (2019) Thalita Santana et al. HUMAN PATHOLOGY
- Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients
- (2019) Wim Boxtel et al. INTERNATIONAL JOURNAL OF CANCER
- Expression pattern of androgen receptor and AR-V7 in androgen deprivation therapy naïve salivary duct carcinomas
- (2018) Richard K. Yang et al. HUMAN PATHOLOGY
- Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma
- (2018) Hideaki Takahashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands
- (2017) Eline Boon et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?
- (2017) Salvatore Alfieri et al. ORAL ONCOLOGY
- Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification
- (2017) Soichiro Takase et al. Oncotarget
- Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer
- (2017) Licai He et al. Scientific Reports
- AR Signaling in Breast Cancer
- (2017) Bilal Rahim et al. Cancers
- Androgen Receptor Signaling in Salivary Gland Cancer
- (2017) Martin Dalin et al. Cancers
- Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
- (2016) M. G. Dalin et al. CLINICAL CANCER RESEARCH
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative
- (2015) Jan Bogaerts et al. EUROPEAN JOURNAL OF CANCER
- Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers
- (2015) Laura D. Locati et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Abiraterone in Metastatic Salivary Duct Carcinoma
- (2015) Damien Urban et al. Journal of the National Comprehensive Cancer Network
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy
- (2014) Laura D Locati et al. CANCER BIOLOGY & THERAPY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now